GlassScriptPhysician profile
Jacob Offenberger
NPI 1033121249
$419,488.11
in general payments reported to CMS, 2019-2025
48 companies · $110K in 2025
The $110K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28K · 2020: $13K · 2021: $14K · 2022: $31K · 2023: $67K · 2024: $156K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $288K · Food and Beverage: $22K · Travel and Lodging: $14K · Consulting Fee: $9,214 · Education: $5.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $287,747.00 |
| Food and Beverage | $22,393.08 |
| Travel and Lodging | $13,789.81 |
| Consulting Fee | $9,214.02 |
| Education | $5.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $181,339.77 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $65,681.51 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $47,754.88 | 2019-2025 | Arexvy, Nucala, Trelegy Ellipta |
| Incyte Corporation | $35,692.09 | 2022-2025 | Opzelura, Opzelura |
| Optinose US, INC. | $21,286.93 | 2019-2024 | |
| Ionis Pharmaceuticals, INC. | $15,620.44 | 2025 | Dawnzera |
| Genentech USA, INC. | $13,300.89 | 2019-2025 | Xolair |
| Genzyme Corporation | $9,933.24 | 2019-2025 | |
| Pfizer INC. | $6,013.96 | 2020-2025 | |
| Shire North American Group INC | $3,991.73 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $3,198.00 | 2025 | Dupixent |
| Biocryst Pharmaceuticals, INC. | $2,528.64 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $2,194.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $1,708.27 | 2019-2025 | |
| Amgen INC. | $1,504.88 | 2021-2025 | Tezspire |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,039.15 | 2020-2025 | Cinryze, Takhzyro, Cuvitru |
| Biocryst US Sales Co., LLC | $958.85 | 2022-2025 | Orladeyo |
| Csl Behring | $818.86 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Octapharma USA, INC. | $612.92 | 2019-2025 | Panzyga, Octagam Immune Globulin (Human), Cutaquig |
| Eyevance Pharmaceuticals LLC | $525.44 | 2020 | |
| Pharming Healthcare, INC. | $504.21 | 2019-2025 | Ruconest |
| Blueprint Medicines Corporation | $403.15 | 2023-2025 | Ayvakit |
| Consortium of Independent Immunology Clinics, LLC | $400.00 | 2024 | |
| Abbvie INC. | $302.58 | 2022-2023 | |
| Alk-Abello, INC | $254.00 | 2019-2023 | Grastek, Ragwitek, Odactra |
| Hikma Pharmaceuticals USA | $246.80 | 2021-2025 | Ryaltris, Kloxxado |
| Leo Pharma INC. | $170.26 | 2022-2025 | Adbry |
| Tersera Therapeutics LLC | $169.40 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $160.31 | 2019-2023 | |
| Galderma Laboratories, L.P. | $148.75 | 2025 | Nemluvio |
| Ars Pharmaceuticals Operations, INC. | $121.78 | 2025 | Neffy |
| Horizon Therapeutics Plc | $110.97 | 2019-2022 | |
| Kaleo, INC. | $108.16 | 2019-2024 | Auvi-Q |
| Organon LLC | $97.33 | 2025 | Vtama |
| Grifols USA, LLC | $91.22 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Aimmune Therapeutics, INC. | $60.99 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.57 | 2023 | Spiriva Respimat |
| Arcutis Biotherapeutics, INC. | $55.56 | 2025 | Zoryve |
| Lilly USA, LLC | $52.81 | 2025 | Ebglyss, Taltz |
| Greer Laboratories, INC. | $50.41 | 2025 | Oralair |
| Abbott Laboratories | $47.04 | 2019 | |
| Phadia US INC. | $42.56 | 2021-2022 | |
| Adma Biomanufacturing LLC | $26.02 | 2024-2025 | |
| Alkermes, INC. | $24.10 | 2021 | |
| Sunovion Pharmaceuticals INC. | $24.03 | 2019 | |
| Gc Biopharma USA, INC. | $23.55 | 2025 | Alyglo |
| Cycle Pharmaceuticals INC | $17.00 | 2025 | Sajazir |
| Biohaven Pharmaceutical Holding Company LTD. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$13,676.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Offenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.